EVO756
Chronic Spontaneous Urticaria
Key Facts
About Evommune
Evommune is a clinical-stage biotech focused on evolving immunology by developing innovative oral therapies for chronic inflammatory diseases with significant unmet need. The company is led by industry veterans and is advancing a pipeline of two primary candidates, EVO756 (targeting MRGPRX2) and EVO301 (targeting IL-18), across multiple indications. Recent milestones include positive Phase 2a data for EVO301 in atopic dermatitis and a $125 million private placement in early 2026 to fund ongoing clinical development.
View full company profileAbout Evommune
Evommune is a clinical-stage biotech focused on evolving immunology by developing innovative oral therapies for chronic inflammatory diseases with significant unmet need. The company is led by industry veterans and is advancing a pipeline of two primary candidates, EVO756 (targeting MRGPRX2) and EVO301 (targeting IL-18), across multiple indications. Recent milestones include positive Phase 2a data for EVO301 in atopic dermatitis and a $125 million private placement in early 2026 to fund ongoing clinical development.
View full company profileAbout Evommune
Evommune is a clinical-stage biotech focused on evolving immunology by developing innovative oral therapies for chronic inflammatory diseases with significant unmet need. The company is led by industry veterans and is advancing a pipeline of two primary candidates, EVO756 (targeting MRGPRX2) and EVO301 (targeting IL-18), across multiple indications. Recent milestones include positive Phase 2a data for EVO301 in atopic dermatitis and a $125 million private placement in early 2026 to fund ongoing clinical development.
View full company profileAbout Evommune
Evommune is a clinical-stage biotech focused on evolving immunology by developing innovative oral therapies for chronic inflammatory diseases with significant unmet need. The company is led by industry veterans and is advancing a pipeline of two primary candidates, EVO756 (targeting MRGPRX2) and EVO301 (targeting IL-18), across multiple indications. Recent milestones include positive Phase 2a data for EVO301 in atopic dermatitis and a $125 million private placement in early 2026 to fund ongoing clinical development.
View full company profile